Eli Lilly & Incyte v. Aurobindo & MSN: Baricitinib Patent Dispute Ends in Dismissal
Eli Lilly and Incyte filed suit in Delaware District Court alleging infringement of two patents covering Olumiant® (baricitinib) tablets against generic challengers Aurobindo Pharma and MSN. After 632 days of litigation, the claims against MSN were dismissed without prejudice by stipulation, with each side bearing its own costs.
Hatch-Waxman baricitinib battle ends without merits ruling against MSN
On 24 August 2022, Eli Lilly & Company and Incyte Corporation (co-patent holders on baricitinib) filed suit in the District of Delaware against Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., MSN Laboratories Private Limited, and MSN Pharmaceuticals Inc., asserting infringement of US8420629B2 and US8158616B2 — patents covering the JAK inhibitor compound baricitinib sold as Olumiant® in 1 mg and 2 mg tablet strengths. The case was assigned to Judge Jennifer L. Hall.
On 17 May 2024, the court entered a stipulated dismissal without prejudice as to MSN Laboratories and MSN Pharmaceuticals only, pursuant to Federal Rules of Civil Procedure 41(a)(1) and 41(c). The order explicitly does not resolve claims against Aurobindo. Each party bears its own legal costs, meaning no fee-shifting was agreed as part of the resolution with MSN.
The 632-day duration before reaching this partial resolution is consistent with strategic Hatch-Waxman litigation timelines, where the 30-month stay mechanism shapes settlement incentives. The without-prejudice nature of the dismissal is notable: it preserves plaintiffs’ ability to re-assert these claims against MSN should a generic product launch occur, and leaves open the possibility of a confidential settlement or licensing arrangement that the public record does not reveal. Proceedings against Aurobindo appear to remain active in the consolidated action.
Filing to Dismissed without Prejudice in 632 days
632 days — longer than median Hatch-Waxman first-instance resolutions, suggesting complex patent negotiations
Dismissed without prejudice as to MSN: what the stipulation means
Rule 41 dismissal without prejudice — no merits ruling
A dismissal without prejudice under FRCP 41(a)(1) and 41(c) terminates the current action without adjudicating the underlying patent claims on their merits. Crucially, it leaves the door open for plaintiffs to re-file identical claims against MSN in a future action. No court finding on validity, infringement, or enforceability of US8420629B2 or US8158616B2 was issued.
No merits adjudicationPlaintiffs retain right to re-assert against MSN
Eli Lilly and Incyte preserved their patent positions by securing a without-prejudice dismissal. They can re-file against MSN if and when MSN attempts a commercial launch of generic baricitinib. This outcome is consistent with a confidential licensing or standstill arrangement, though the public record is silent on whether any such agreement exists. Prosecution against Aurobindo continues separately.
Claims preservedMSN exits this action but faces lingering patent risk
MSN Laboratories and MSN Pharmaceuticals obtained dismissal of the current action, but the without-prejudice nature means they cannot treat this as a clean IP clearance. Any commercial launch of a generic baricitinib product would likely trigger a new infringement suit. The mutual cost-bearing provision suggests neither side gained significant leverage in the negotiated exit.
Exposure not eliminatedBaricitinib generic entry remains legally uncertain
With claims against MSN dismissed without prejudice and Aurobindo proceedings ongoing in the same consolidated action, the path to generic baricitinib entry remains legally clouded. Originators Lilly and Incyte retain the ability to reinstate litigation against MSN rapidly. Market participants monitoring generic competition for Olumiant® should treat this partial dismissal as a pause, not a resolution.
Generic entry risk persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Eli Lilly & Company | Company | Pharma innovator & JAK inhibitor co-patent holder — holder of US8420629B2Search in Eureka ↗ |
| Co-Plaintiff | Incyte Holdings Corporation | Company | Search in Eureka ↗ |
| Co-Plaintiff | Incyte Corporation | Company | Search in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | Indian generic pharmaceutical manufacturer seeking U.S. market entry for baricitinib tabletsSearch in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Laboratories Private Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | MSN Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Eli Lilly & CompanySearch in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Eli Lilly & CompanySearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Eli Lilly & CompanySearch in Eureka ↗ |
| Defendant counsel | Michael P. Hogan | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | R. Touhey Myer | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | Timothy H. Kratz | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | Kratz & Barry LLP | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal order is carefully scoped: it applies only to MSN entities and expressly excludes Aurobindo, confirming this is a partial resolution within a consolidated multi-defendant action. The mutual cost-bearing provision is standard in negotiated Hatch-Waxman exits and avoids any implication of a prevailing party. The without-prejudice designation means the baricitinib patent claims under US8420629B2 and US8158616B2 remain live enforcement tools against MSN, preserving plaintiffs’ full Paragraph IV litigation rights.
US8420629B2 & US8158616B2 — Baricitinib JAK inhibitor compound patents
US8420629B2 (application no. US13/315750) and US8158616B2 (application no. US12/401348) cover baricitinib, a selective JAK1 and JAK2 inhibitor developed by Lilly and Incyte. Baricitinib is the active ingredient in Olumiant®, approved by the FDA for rheumatoid arthritis and atopic dermatitis. These patents represent foundational compound and composition protection for a blockbuster immunology asset, placing them at the centre of any generic entry strategy for the U.S. market.
As co-owned foundational patents on a commercialised JAK inhibitor with multi-billion dollar annual revenues, US8420629B2 and US8158616B2 present high-value litigation targets for ANDA filers. The patents’ application dates and grant history make them core Paragraph IV challenge candidates. Any generic pharmaceutical company seeking baricitinib market entry must carefully evaluate both patents’ claim scope, remaining term, and any available patent term extensions before filing.
Should you run an FTO analysis against US8420629B2 and US8158616B2?
Any pharmaceutical company developing a generic or follow-on JAK inhibitor product — particularly baricitinib formulations — should treat US8420629B2 and US8158616B2 as mandatory FTO checkpoints. These patents remain unadjudicated on the merits; no court has found them invalid or not infringed. Generic manufacturers, ANDA applicants, and biosimilar developers working in the JAK inhibitor space face direct infringement exposure until expiry or successful invalidation.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US8420629B2 and US8158616B2, identify prosecution history estoppel risks, surface prior art relevant to validity challenges, and flag related continuations or divisionals that may extend the family’s coverage. R&D and regulatory teams can use Eureka to monitor patent status changes, PTE filings, and litigation events across the Olumiant® patent portfolio in real time.
Run a freedom-to-operate analysis on US8420629B2 to assess your product’s exposure
Run FTO in Eureka →Similar JAK inhibitor Hatch-Waxman patent cases in Delaware
Related Paragraph IV infringement actions involving JAK inhibitor patents and generic pharmaceutical challengers litigated in the District of Delaware.
What this case signals for the JAK inhibitor generic IP landscape
A partial without-prejudice dismissal in a Hatch-Waxman JAK inhibitor case carries distinct strategic implications for both innovators and generic challengers.
Without-prejudice exits are common Hatch-Waxman holding patterns
In Paragraph IV litigation, without-prejudice dismissals often signal a negotiated standstill or licensing arrangement rather than a genuine concession by either side. IP teams monitoring baricitinib generics should treat this resolution as a signal that plaintiffs retain full enforcement capability against MSN upon any product launch.
Aurobindo proceedings still active — full picture remains incomplete
The consolidated action against Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. was expressly excluded from this stipulation. Until those claims are resolved, the enforceability and validity of US8420629B2 and US8158616B2 have not been tested in court, maintaining legal uncertainty for all generic challengers.
Eli v Aurobindo — key questions answered
The claims against MSN Laboratories Private Limited and MSN Pharmaceuticals Inc. were dismissed without prejudice by stipulation on 17 May 2024. No merits ruling was issued on the baricitinib patents. Claims against Aurobindo Pharma were explicitly excluded from this dismissal order and the consolidated action continues.
Two patents are asserted: US8420629B2 (application US13/315750) and US8158616B2 (application US12/401348). Both cover baricitinib, the JAK1/JAK2 inhibitor sold as Olumiant® by Eli Lilly in 1 mg and 2 mg tablet strengths for inflammatory conditions including rheumatoid arthritis.
Dismissed without prejudice means Eli Lilly and Incyte can re-file patent infringement claims against MSN at any time, particularly if MSN attempts to commercially launch a generic baricitinib product. The dismissal does not constitute patent clearance. Generic entry risk under these patents remains legally unresolved.
No. The stipulated dismissal order expressly states it applies only to Plaintiffs and MSN and not to any other party in the consolidated action. Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. remain defendants, and the underlying patent claims against them are unaffected by the MSN resolution.
Eli Lilly and Incyte were represented by Jack B. Blumenfeld and Jeremy A. Tigan of Morris, Nichols, Arsht & Tunnell LLP. MSN was represented by Michael P. Hogan, R. Touhey Myer, and Timothy H. Kratz of Kratz & Barry LLP. Judge Jennifer L. Hall presided over the case in the District of Delaware.
PatSnap Eureka searches patents and litigation data to answer instantly.